Emerald Health Therapeutics and Skye Bioscience Close Plan of Arrangement
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") announced today that its Plan of Arrangement with Skye Bioscience, Inc. ("Skye") has closed and that it has entered into agreements to divest its remaining cannabis assets and licenses, including its Quebec cannabis production facility."The closing of the Plan of Arrangement and agreements to divest the Company's cannabis production...
2022-11-10 10:48 PM EST
Emerald Health Therapeutics and Skye Bioscience Announce Intended Closing Date of Plan of Arrangement
Vancouver, British Columbia--(Newsfile Corp. - November 7, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") and Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye") announced today that they intend to close the previously announced Plan of Arrangement ("Arrangement") on or about November 10, 2022, and that they waived the condition that Skye obtain a conditional approval to list its shares on the Canadian Securities Exchange ("CSE") prior to closing the...
2022-11-07 4:35 PM EST
Emerald Health Therapeutics Announces Bridge Loan to Skye Bioscience and Provides Update on Merger
Vancouver, British Columbia--(Newsfile Corp. - October 18, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") reports that it has provided a short-term bridge loan of US$700,000 to Skye Bioscience, Inc. ("Skye") in order to provide Skye with additional working capital until the closing of their Arrangement.On May 11, 2022, Emerald and SKYE entered into an Arrangement Agreement (as subsequently amended) pursuant to which Skye will acquire all of...
2022-10-18 7:00 AM EDT
Emerald Health Therapeutics, Inc. Reports 2022 Q2 Results
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") has reported financial results for the quarter ended June 30, 2021. Selected Financial Information The financial information presented for the years below was derived from financial statements prepared in accordance with IFRS and is expressed in Canadian dollars.Reported in $000s
2022-08-31 7:00 AM EDT
Emerald Health Therapeutics Receives Court Approval of Plan of Arrangement with Skye Bioscience
Vancouver, British Columbia--(Newsfile Corp. - August 26, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") reports that on August 25, 2022, the Supreme Court of British Columbia issued a final order approving the Company's previously announced plan of arrangement (the "Arrangement") with Skye Bioscience Inc. ("Skye") (OTCQB: SKYE) and declaring that the Arrangement was procedurally and substantively fair and reasonable. The Arrangement was...
2022-08-26 7:00 AM EDT
Emerald Health Therapeutics Shareholders Vote in Favour of Plan of Arrangement with Skye Bioscience
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") reports that its shareholders voted in favour of all resolutions presented at its annual and special meeting held today at 10:00 am PT.The resolution to approve the proposed plan of arrangement (the "Arrangement") with Skye Bioscience Inc. ("Skye") (OTCQB: SKYE) was approved by 87.07% of votes cast by shareholders for that resolution. The...
2022-08-19 2:12 PM EDT
Emerald Health Therapeutics, Inc. Provides Update on and Additional Background to Transaction with Skye Bioscience
Vancouver, British Columbia--(Newsfile Corp. - August 12, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") is providing an update and additional background on its transaction (the "Transaction") with Skye Bioscience Inc. (OTCQB: SKYE) ("Skye") pursuant to the terms of an arrangement agreement dated May 11, 2022, as amended (the "Arrangement Agreement").On July 28, 2022, Emerald mailed to shareholders of Emerald (the "EHT Shareholders") its...
2022-08-12 7:00 AM EDT
Emerald Health Therapeutics, Inc. Restates Q1 Financial Statements to Meet PCAOB Standard
Vancouver, British Columbia--(Newsfile Corp. - August 12, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") announces that it has identified matters which require the Company to make restatements (the "Restatements") in respect of its interim consolidated financial statements for the three months ended March 31, 2022 and 2021 (the "Restated Q1 Financial Statements") and related management discussion and analysis (the "Restated MD&A") relating to...
2022-08-12 6:55 AM EDT
Emerald Health Therapeutics Announces Revocation of Management Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - July 12, 2022) - Emerald Health Therapeutics, Inc. ("Emerald" or the "Company") (CSE: EMH) (OTCQB: EMHTF) reports that it has received an Order of the British Columbia Securities Commission ("BCSC") revoking the management cease trade order ("MCTO") issued by the BCSC on May 3, 2022.On April 28, 2022, the Company announced that it had applied to the BCSC for a management cease trade order ("MCTO") on the basis that the Company would be unable to...
2022-07-12 7:00 AM EDT
Emerald Health Therapeutics, Inc. Reports 2022 Q1 Results
Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") has reported financial results for the quarter ended March 31, 2021. Through the first quarter of 2022 the Company continued to execute on its transition from the recreational and medical cannabis business to pharmaceutical development, as announced on November 29, 2021. Selected Financial Information The financial information presented for...
2022-07-11 7:00 AM EDT
Emerald Health Therapeutics, Inc. Reports 2021 Year-End Results and Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - July 4, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") has reported financial results for the year ended December 31, 2021, and an update on strategic corporate activities subsequent to year-end.The Company continued to operate as a recreational and medical cannabis business in Canada throughout 2021. Details of these operations and results are provided in Emerald's audited financial statements...
2022-07-04 7:00 AM EDT
Emerald Health Therapeutics Provides Bi-Weekly MCTO Status Update
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Management Cease Trade Orders ("NP 12-203").On April 28, 2022, the Company announced that it had applied for a management cease trade order (an "MCTO") with the British Columbia Securities Commission on the basis...
2022-06-16 7:00 AM EDT
Emerald Health Therapeutics, Inc. Provides Second Bi-Weekly MCTO Status Update
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald" or the "Company") is providing a status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Management Cease Trade Orders ("NP 12-203").On April 28, 2022, the Company announced that it had applied for a management cease trade order (a "MCTO") with the British Columbia Securities Commission on the basis that the...
2022-06-03 7:00 AM EDT
Emerald Health Therapeutics, Inc. Provides Bi-Weekly MCTO Status Update
Vancouver, British Columbia--(Newsfile Corp. - May 16, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Management Cease Trade Orders ("NP 12-203").On April 28, 2022, the Company announced that it had applied for a management cease trade order (a "MCTO") with the British Columbia Securities Commission on the basis...
2022-05-16 4:05 PM EDT
Emerald Health Therapeutics Signs Arrangement Agreement with Skye Bioscience
Arrangement is expected to fund Skye's proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to start later in 2022Preclinical studies have demonstrated potential advantages of Skye's unique, patent-protected therapeutic drug, SBI-100 Ophthalmic Emulsion, compared to the standard of careVancouver, British Columbia--(Newsfile Corp. - May 12, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald")...
2022-05-12 8:50 AM EDT
Emerald Health Therapeutics, Inc. Transfers US Listing to OTCQB
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") announced today that it has transferred its US listing to the OTCQB after receiving notice from the OTC Markets Group that the Company no longer meets the listing requirements for continued listing on the OTCQX International tier.On November 3, 2021, Emerald received notice that the Company's bid price had closed below $0.10 for more than 30...
2022-05-06 7:00 AM EDT
Emerald Health Therapeutics, Inc. Applies for Management Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - April 28, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald" or the "Company") reports that it anticipates it will be unable to file its Annual Filings before the May 2, 2022 deadline and has applied to the British Columbia Securities Commission for a temporary management cease trade order.Under the provisions of Parts 4 and 5 of National Instrument 51-102 - Continuous Disclosure Obligations ("NI 51-102"), Emerald is...
2022-04-28 7:00 AM EDT
Emerald Health Therapeutics Sells Patents to FlowerPod
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") has entered into a binding term sheet to sell to FlowerPod LLC all patents and related intellectual property pertaining to Emerald's vaporizer cannabis puck concept in exchange for US$1 million in cash and a US$500,000 one-year interest-bearing secured promissory note. As part of the transaction, Emerald will transfer its ownership interest back to...
2022-01-11 7:00 AM EST
Emerald Health Therapeutics Reports 2021 AGM Results
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") has announced the results of voting at its annual general meeting held December 30, 2021. Shareholders voted in favour of all resolutions, setting the number of directors at three, electing Jim Heppell, Punit Dhillon and Bobby Rai as directors, and appointing MNP LLP as auditors of the Company for the ensuing year and authorizing the directors to fix...
2021-12-31 7:00 AM EST
Emerald Health Therapeutics Pivots Out of Recreational and Medical Cannabis and into Pharmaceutical Development
Vancouver, British Columbia--(Newsfile Corp. - November 29, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald" or the "Company") today announced that it is exiting the recreational and medical cannabis business and pivoting to a pharmaceutical development focus. Emerald intends to seek purchasers for its recreational and medical cannabis assets to further strengthen its already strong capital position and plans significant cost cuts to decrease its monthly net...
2021-11-29 7:00 AM EST